12.95
-0.0544(-0.42%)
Currency In USD
| Previous Close | 13 |
| Open | 13.08 |
| Day High | 13.08 |
| Day Low | 12.95 |
| 52-Week High | 14 |
| 52-Week Low | 6.55 |
| Volume | 1,824 |
| Average Volume | 28,732 |
| Market Cap | 64.53M |
| PE | 80.91 |
| EPS | 0.16 |
| Moving Average 50 Days | 11.78 |
| Moving Average 200 Days | 9.16 |
| Change | -0.05 |
If you invested $1000 in Daxor Corporation (DXR) 10 years ago, it would be worth $1,477.84 as of October 19, 2025 at a share price of $12.946. Whereas If you bought $1000 worth of Daxor Corporation (DXR) shares 5 years ago, it would be worth $886.08 as of October 19, 2025 at a share price of $12.946.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25
GlobeNewswire Inc.
Oct 15, 2025 12:00 PM GMT
OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall’25 Conference b
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
GlobeNewswire Inc.
Sep 30, 2025 12:00 PM GMT
Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood vo
Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
GlobeNewswire Inc.
Sep 23, 2025 12:00 PM GMT
Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement OAK RIDGE, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announ